Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, Korea, discusses optimizing adjuvant treatment in HR-positive, HER2-negative early breast cancer. Assessing patients’ Ki-67 score and genetic signature helps to guide optimal treatment and predict long-term outcomes of endocrine therapy to a more accurate degree than clinical and pathologic complete response (pCR). Dr Kim additionally notes on how neoadjuvant endocrine therapy is a good alternative to neoadjuvant chemotherapy for patients with HR-positive breast cancer. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.
Paolo Tarantino, MD, European Institute of Oncology IRCCS, Milan, Italy, talks on the Phase III monarchE (NCT03155997) trial which investigated abemaciclib in participants with high-risk, node positive, early stage, HR-positive, HER2-negative, breast cancer. 11% of patients in a cohort of over 5000 were eligible for adjuvant abimacyclib. This patient population was characterized by young age and BRCA2 mutations, meaning they may also be eligible to receive olaparib as adjuvant treatment. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.
Michael Gnant, MD, Medical University of Vienna, Vienna, Austria, shares the final results from the randomized, Phase III PALLAS trial (NCT02513394). PALLAS investigated whether the addition of the CDK4/6 inhibitor, palbociclib, to adjuvant endocrine therapy improves outcomes over endocrine therapy alone in patients with hormone receptor-positive, HER2-negative early breast cancer. The addition of palbociclib did not improve survival endpoints in this patient population; whether the addition of CDK4/6 inhibition to particular subgroups of patients is being investigated. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.